Biotech | February 17, 2022
Center for Breakthrough Medicines launches analytical testing
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Subscribe To Our Newsletter & Stay Updated
